# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Hubert H. Humphrey (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML022-SYN-TD
- Date: 1977-01-06
- Fictional facility: St. Posthumous Health Center
- Fictional author: Walter Brandvold, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

First visit to establish shared care three months after radical cystoprostatectomy with an ileal conduit for bladder cancer. **S**

## Historical basis

- Hubert Horatio Humphrey Jr. was born on 27 May 1911 in Wallace, South Dakota. **D**
- Humphrey served in the U.S. Senate from Minnesota from 1949 to 1964, as vice president from 1965 to 1969, and again in the Senate from 1971 until his death. **D**
- Humphrey sought medical advice in 1967 for blood in his urine; some doctors suspected bladder cancer, others disagreed, and he was not treated. In 1968 doctors found and removed several pinhead-size nonmalignant growths from his bladder. In 1994 researchers reported a p53 gene mutation in bladder cells from a 1967 urine sample of his. **D**
- In 1973 doctors found possibly cancerous tissue in his bladder and treated it with thiotepa and X-ray therapy, given five minutes a day for five weeks. **D**
- After three years free of cancer, an examination at the National Naval Medical Center in Bethesda for symptoms of a urinary tract infection found a low-grade malignancy, and in October 1976 a six-hour radical cystectomy at Memorial Sloan-Kettering Cancer Center removed his bladder, prostate, lymph nodes, the fatty tissue around the bladder, and part of the urethra; the ureters were joined to a conduit made from a segment of small intestine, brought out to an opening on the skin to the right of the navel and drained into a bag. The nodes were to be examined for spread, and an experimental two-drug chemotherapy might be offered. **D**
- He resumed his Senate duties in January 1977, serving as deputy president pro tempore from January 5, 1977. **D**

2 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Wants his follow-up after bladder removal and his urostomy managed close to home and work. **S**
- Bothered by appliance leaks and sore skin around the stoma, which interrupt his long working days. **S**

## Strengths and supports

- Supports: family, close friends, and a large circle of colleagues **S**

## Medications and allergies

- No medications before this visit. **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1967: Blood in the urine; bladder cancer suspected by some physicians but not treated **D** (CLM-0003)
- 1968: Several small benign bladder growths found and removed **D** (CLM-0003)
- 1973: Possibly cancerous bladder tissue treated with thiotepa and X-ray therapy, five minutes a day for five weeks **D** (CLM-0004)
- October 1976: Radical cystectomy with removal of the prostate, lymph nodes, and part of the urethra, and a urinary conduit made from small intestine, after a low-grade malignancy was found on examination for urinary infection symptoms **D** (CLM-0005)

## Procedures and immunizations

- 1976-09-02 to 1976-09-02: Cystoscopy and transurethral resection of bladder tumors, at the cancer center: recurrent multifocal papillary urothelial carcinoma, low grade, with high-grade carcinoma in situ in random biopsies; muscularis propria present and not invaded (cTa with CIS); small, poorly compliant bladder after earlier radiation **S**
- 1976-09-16 to 1976-09-16: Staging CT of the chest, abdomen, and pelvis with CT urography: thickened bladder wall; no hydronephrosis, upper-tract filling defect, enlarged lymph nodes, or distant disease **S**
- 1976-10-07 to 1976-10-07: Radical cystoprostatectomy with bilateral pelvic lymph node dissection, partial urethrectomy, and ileal conduit urinary diversion, stoma in the right lower abdomen, at the cancer center. Pathology: multifocal urothelial carcinoma, high grade, with carcinoma in situ, invading the inner half of the muscularis propria (pT2a); 0 of 18 lymph nodes (pN0); ureteric and urethral margins negative; prostate with benign hyperplasia and no urothelial involvement **S**
- 1976-11-18: High-dose influenza vaccine, this season **S**
- 1971-03-10: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

Sodium: 139 mmol/L; Potassium: 4.3 mmol/L; Chloride: 106 mmol/L; Bicarbonate (total CO2): 22 mmol/L; Urea nitrogen: 18 mg/dL; Creatinine: 1.12 mg/dL; eGFR: 73 mL/min/1.73 m²; Calcium: 9.2 mg/dL; Albumin: 3.7 g/dL; Alkaline phosphatase: 88 U/L; ALT: 22 U/L; Hemoglobin: 12.6 g/dL (low); White cell count: 6.4 10*3/uL; Platelets: 284 10*3/uL; Vitamin B12: 412 pg/mL; PHQ-9: 3. All results are synthetic.

BP 126/76 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 97% on room air; weight 76.5 kg; BMI 23.6 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, talkative, and optimistic; asks detailed questions about his results; Mood good; PHQ-9 minimal at the first visit. Functional status: Independent in all activities of daily living, including emptying and changing his urostomy appliance; Walks 20 minutes a day, building up after surgery. Physical examination is intentionally limited. **S**

## Assessment

1. Urothelial carcinoma of the bladder, multifocal, with carcinoma in situ, pT2a pN0 (0 of 18 nodes), margins negative, treated by radical cystoprostatectomy with an ileal conduit; no evidence of disease; under surveillance; synthetic modern detail linked to his documented bladder cancer; status draft. **S**
2. Ileal conduit urostomy, right lower abdomen; status draft. **S**
3. Acquired absence of the bladder and part of the urethra after radical cystectomy; status draft. **S**
4. Acquired absence of the prostate after cystoprostatectomy; status draft. **S**
5. Personal history of pelvic radiation for bladder tumor, with earlier intravesical thiotepa; status draft. **S**

## Plan

- Urology consultation to share survivorship surveillance after radical cystectomy, review the stoma, and set the metabolic monitoring plan. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026) **S**
- Stoma care with the wound, ostomy, and continence nurse: appliance fitting, peristomal skin care, and parastomal hernia checks. Guideline: Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026); CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026) **S**

## Guideline basis

- Holzbeierlein J, et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/SUO Guideline (2017; Amended 2020, 2024). J Urol 2024;212(1):3-10 (2024), American Urological Association, American Society of Clinical Oncology, and Society of Urologic Oncology
- Holzbeierlein JM, et al. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment. J Urol 2024;211(4):533-538 (2024), American Urological Association and Society of Urologic Oncology
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer (2026), National Comprehensive Cancer Network
- CMID: Clinical Monitoring Intelligence Database, urologic cancer monograph (2026), Aether Forge
